These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 3035023)
21. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment. Yoshida R; Yoneda Y; Kuriyama M; Kubota T J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111 [TBL] [Abstract][Full Text] [Related]
22. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Shu S; Chou T; Rosenberg SA Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046 [TBL] [Abstract][Full Text] [Related]
23. src-specific immune regression of Rous sarcoma virus-induced tumors. Gelman IH; Hanafusa H Cancer Res; 1993 Feb; 53(4):915-20. PubMed ID: 8381333 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes. Comoglio PM; Prat M; Bretti S Immunology; 1985 Feb; 54(2):289-95. PubMed ID: 2578431 [TBL] [Abstract][Full Text] [Related]
25. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222 [TBL] [Abstract][Full Text] [Related]
27. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. Stern JJ; Oca MJ; Rubin BY; Anderson SL; Murray HW J Immunol; 1988 Jun; 140(11):3971-7. PubMed ID: 3131421 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of passive antilisterial immunity and change of Lyt phenotype following in vitro stimulation of murine lymphoid cells from immune donors. Barry RA; Hinrichs DJ Clin Invest Med; 1984; 7(4):303-9. PubMed ID: 6442653 [TBL] [Abstract][Full Text] [Related]
29. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401 [TBL] [Abstract][Full Text] [Related]
30. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636 [TBL] [Abstract][Full Text] [Related]
31. The augmentation of surface Ly-6A/E molecules in activated T cells is mediated by endogenous interferon-gamma. Dumont FJ; Boltz RC J Immunol; 1987 Dec; 139(12):4088-95. PubMed ID: 3121727 [TBL] [Abstract][Full Text] [Related]
32. Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas. Prat M; Di Renzo MF; Comoglio PM Int J Cancer; 1983 Jun; 31(6):757-64. PubMed ID: 6305851 [TBL] [Abstract][Full Text] [Related]
33. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity. Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830 [TBL] [Abstract][Full Text] [Related]
34. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454 [TBL] [Abstract][Full Text] [Related]
35. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target. Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428 [TBL] [Abstract][Full Text] [Related]
36. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Awwad M; North RJ Cancer Res; 1990 Apr; 50(8):2228-33. PubMed ID: 2317810 [TBL] [Abstract][Full Text] [Related]
37. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo. Xiang J; Moyana T Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051 [TBL] [Abstract][Full Text] [Related]
38. Cytolytic activity of murine CD4+ T cell clones correlates with IFN-gamma production in mouse strains having a BALB/c background. McKisic MD; Lancki DW; Fitch FW J Immunol; 1993 May; 150(9):3793-805. PubMed ID: 8097225 [TBL] [Abstract][Full Text] [Related]
39. Adoptive cell transfer studies to examine the role of T lymphocytes in immunity to Trypanosoma musculi. House RV; Dean JH J Parasitol; 1988 Oct; 74(5):819-27. PubMed ID: 2971101 [TBL] [Abstract][Full Text] [Related]
40. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Mizuhara H; Uno M; Seki N; Yamashita M; Yamaoka M; Ogawa T; Kaneda K; Fujii T; Senoh H; Fujiwara H Hepatology; 1996 Jun; 23(6):1608-15. PubMed ID: 8675184 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]